CTNM
NASDAQ
$13.90
Contineum Therapeutics Inc - Class A (CTNM)
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company is headquartered in San Diego, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $22.33 (+60.65%)
Market Cap
$546M
Profit Margin
83.1%
Free Cash Flow Yield
-10.56%
Beta (5Y)
0.75
Price Chart
Valuation
Market Cap$546M
P/S11.15
P/B2.18
Profitability
EBITDA-$67M
Profit Margin83.1%
Operating Margin77.9%
EPS-$2.08
Financial Health
Free Cash Flow Yield-10.56%
Growth & Risk
Beta (5Y)0.75
Sharpe Ratio1.93